Home
Commercial Solutions
Back
Integrated Commercial Services
Back
Advisory Services
Back
Management Consulting
Regulatory Consulting
Specialty Consulting
Canadian Advisory Services
HEOR, Value & Evidence
Patient Services
Back
Access & Hub
Adherence Solutions
Affordability, Co-Pay & PAP
Specialty Pharmacy
In-Home Nursing & Clinical Support
Field Deployment Solutions
Back
Field Deployment Solutions
Medical Deployment Solutions
Learning & Performance Services
Market Access
Back
Market Access Strategies
Market Shaping Activation Model
Market Access & Reimbursement
Market Research & Insights
RWE & HEOR
Pricing & Revenue Management
Back
Global Pricing & Access
Market Access & Reimbursement
수익 관리
Research & Insights
Medical Affairs
Back
Medical Affairs Strategy
Integrated Compliance Solutions
Medical Information
Pharmacovigilance
Quality Assurance/Quality Management Systems
Regulatory
Medical Affairs Technology Innovation
Agency Solutions
Back
Patient, Payer & Provider Marketing Agency
Digital Transformation & Innovation
Omnichannel Platform
Trade, Channel & 3PL
Back
Global Channel Management & 3PL
e-Commerce
Data & Analytics
Back
Data & Analytics Solutions
Commercial Analytics
Integrated Commercial Models
Back
EVERSANA COMPLETE Commercialization®
EVERSANA REIGNITE™
EVERSANA ORCHESTRATE™
EVERSANA COMPLETE Oncology™
Direct-to-Patient Care Model
Value Across Life Cycle
Back
EVERSANA COMPLETE Commercialization®
EVERSANA’s Direct-to-Patient Care Model
Launch Readiness
Product Launch
In Market
Established Brands
Technology & Innovation
Back
NAVLIN
Back
Global Pricing & Access Data
Research & Insights
수익 관리
Price & Access Software
ACTICS
Back
Omnichannel Platform
Patient Relationship Management
ACTICS eAccess
Chronic Disease RWD
EVERSANA ORCHESTRATE™
Quality Management Systems
Donor Eligibility System
Solve Commercial Challenges
Back
Assess Commercial Readiness in Europe
Market Shaping Activation Model
Propel Commercialization with D&A
Reach Patients & Sustain Adherence
Penetrate & Expand Markets
Optimize Product Launch
Ensure Market Access
Maintain Safe & Effective Usage
Mobilize High Performing Sales Force
Distribute in Effective & Efficient Ways
Optimize Pricing & Reimbursement
Achieve Stakeholder Intimacy
Therapeutic Expertise
Back
Oncology & Hematology
Neurology & CNS
Rare
Cell & Gene
Digital Medicines
About
Back
Beliefs
Leaders
전문가
지사 위치
Awards
Events
인사이트
Back
Thought Leadership
Scientific Insights
News
Careers
Search
Select a Region
North America
아시아 태평양
Europe
North America
Contact
menu
Home
Commercial Solutions
Integrated Commercial Services
Advisory Services
Management Consulting
Regulatory Consulting
Specialty Consulting
Canadian Advisory Services
HEOR, Value & Evidence
Patient Services
Access & Hub
Adherence Solutions
Affordability, Co-Pay & PAP
Specialty Pharmacy
In-Home Nursing & Clinical Support
Field Deployment Solutions
Field Deployment Solutions
Medical Deployment Solutions
Learning & Performance Services
Market Access
Market Access Strategies
Market Shaping Activation Model
Market Access & Reimbursement
Market Research & Insights
RWE & HEOR
Pricing & Revenue Management
Global Pricing & Access
Market Access & Reimbursement
수익 관리
Research & Insights
Medical Affairs
Medical Affairs Strategy
Integrated Compliance Solutions
Medical Information
Pharmacovigilance
Quality Assurance/Quality Management Systems
Regulatory
Medical Affairs Technology Innovation
Agency Solutions
Patient, Payer & Provider Marketing Agency
Digital Transformation & Innovation
Omnichannel Platform
Trade, Channel & 3PL
Global Channel Management & 3PL
e-Commerce
Data & Analytics
Data & Analytics Solutions
Commercial Analytics
Integrated Commercial Models
EVERSANA COMPLETE Commercialization®
EVERSANA REIGNITE™
EVERSANA ORCHESTRATE™
EVERSANA COMPLETE Oncology™
Direct-to-Patient Care Model
Value Across Life Cycle
EVERSANA COMPLETE Commercialization®
EVERSANA’s Direct-to-Patient Care Model
Launch Readiness
Product Launch
In Market
Established Brands
Technology & Innovation
NAVLIN
Global Pricing & Access Data
Research & Insights
수익 관리
Price & Access Software
ACTICS
Omnichannel Platform
Patient Relationship Management
ACTICS eAccess
Chronic Disease RWD
EVERSANA ORCHESTRATE™
Quality Management Systems
Donor Eligibility System
Solve Commercial Challenges
Assess Commercial Readiness in Europe
Market Shaping Activation Model
Propel Commercialization with D&A
Reach Patients & Sustain Adherence
Penetrate & Expand Markets
Optimize Product Launch
Ensure Market Access
Maintain Safe & Effective Usage
Mobilize High Performing Sales Force
Distribute in Effective & Efficient Ways
Optimize Pricing & Reimbursement
Achieve Stakeholder Intimacy
Therapeutic Expertise
Oncology & Hematology
Neurology & CNS
Rare
Cell & Gene
Digital Medicines
About
Beliefs
Leaders
전문가
지사 위치
Awards
Events
인사이트
Thought Leadership
Scientific Insights
News
Careers
Search
Newscenter
Browsing Archive: Scientific InsightsScientific Insights | EVERSANA - Part 10
Posted on
1월 25, 2023
1/25/23
Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder
Posted on
1월 25, 2023
1/25/23
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry
Posted on
1월 25, 2023
1/25/23
P45 Internal, External, and Cross-Validation of the DEDUCE Model, a Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes
Posted on
1월 25, 2023
1/25/23
P45 Internal, External, and Cross-Validation of the DEDUCE Model, a Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes
Posted on
1월 25, 2023
1/25/23
Unmet Need in People with Psoriasis and Skin of Color in Canada and the United States
Posted on
1월 25, 2023
1/25/23
Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.
Posted on
1월 2, 2023
1/2/23
“Economic analysis of n-butyl cyanoacrylate compared with ethylene vinyl alcohol copolymer liquid embolic embolization of brain arteriovenous malformations (bAVMs) from a US hospital perspective”
Posted on
1월 2, 2023
1/2/23
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
Posted on
1월 2, 2023
1/2/23
An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective
Posted on
1월 2, 2023
1/2/23
Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
페이지 10 의 12
« 처음
«
...
8
9
10
11
12
»
Scientific Insights